tiprankstipranks
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris announces publications of efficacy, safety evidence on deucrictibant
The FlyPharvaris announces publications of efficacy, safety evidence on deucrictibant
9d ago
PHVS
Pharvaris reports results from study of patient experience during HAE attacks
PremiumThe Fly
Pharvaris reports results from study of patient experience during HAE attacks
18d ago
PHVS
Pharvaris initiated with an Outperform at RBC Capital
PremiumThe Fly
Pharvaris initiated with an Outperform at RBC Capital
20d ago
PHVS
Pharvaris participates in a conference call hosted by Cantor Fitzgerald
PremiumThe Fly
Pharvaris participates in a conference call hosted by Cantor Fitzgerald
1M ago
PHVS
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
PremiumRatings
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
3M ago
PHVS
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
PremiumCompany AnnouncementsPharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
3M ago
6K
PHVS
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
3M ago
IMNM
KYTX
Pharvaris price target raised to $50 from $44 at Oppenheimer
Premium
The Fly
Pharvaris price target raised to $50 from $44 at Oppenheimer
4M ago
KALV
PHVS
Pharvaris price target raised to $39 from $32 at Guggenheim
PremiumThe Fly
Pharvaris price target raised to $39 from $32 at Guggenheim
4M ago
PHVS
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
PremiumRatings
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
4M ago
PHVS
Pharvaris price target raised to $30 from $27 at BofA
PremiumThe Fly
Pharvaris price target raised to $30 from $27 at BofA
4M ago
PHVS
Pharvaris price target raised to $41 from $37 at Morgan Stanley
PremiumThe Fly
Pharvaris price target raised to $41 from $37 at Morgan Stanley
4M ago
PHVS
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
PremiumRatingsPharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
4M ago
PHVS
Pharvaris price target raised to $38 from $28 at Leerink
Premium
The Fly
Pharvaris price target raised to $38 from $28 at Leerink
4M ago
PHVS
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
Premium
The Fly
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
4M ago
M
W
Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
PremiumRatings
Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
4M ago
PHVS
Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment
PremiumRatings
Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment
4M ago
PHVS
Morning Movers: Macy’s dips following third quarter earnings report
PremiumThe Fly
Morning Movers: Macy’s dips following third quarter earnings report
4M ago
M
AEO
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
PremiumCompany Announcements
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
4M ago
6K
PHVS
Pharvaris’ deucrictibant meets primary endpoint in HAE attack trial
PremiumThe FlyPharvaris’ deucrictibant meets primary endpoint in HAE attack trial
4M ago
PHVS
Pharvaris Reports Q3 2025 Financial Results and Updates
Premium
Company Announcements
Pharvaris Reports Q3 2025 Financial Results and Updates
4M ago
PHVS
Pharvaris: Strong Buy Rating Backed by Promising Clinical Trials and Robust Financial Health
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Promising Clinical Trials and Robust Financial Health
4M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >